Cornercap Investment Counsel Inc. Makes New Investment in Anika Therapeutics, Inc. (NASDAQ:ANIK)

Cornercap Investment Counsel Inc. purchased a new stake in Anika Therapeutics, Inc. (NASDAQ:ANIK) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 9,653 shares of the biotechnology company’s stock, valued at approximately $238,000. Cornercap Investment Counsel Inc. owned approximately 0.07% of Anika Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. BNP Paribas Financial Markets increased its holdings in Anika Therapeutics by 16.9% during the 1st quarter. BNP Paribas Financial Markets now owns 22,240 shares of the biotechnology company’s stock valued at $565,000 after acquiring an additional 3,217 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Anika Therapeutics by 7.8% during the 1st quarter. SG Americas Securities LLC now owns 8,615 shares of the biotechnology company’s stock worth $219,000 after purchasing an additional 627 shares during the last quarter. State Board of Administration of Florida Retirement System purchased a new stake in Anika Therapeutics in the 1st quarter valued at approximately $198,000. Vanguard Group Inc. grew its holdings in Anika Therapeutics by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 773,702 shares of the biotechnology company’s stock valued at $19,652,000 after buying an additional 9,657 shares during the last quarter. Finally, Lazard Asset Management LLC purchased a new position in Anika Therapeutics during the first quarter worth $180,000. Institutional investors and hedge funds own 91.53% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ANIK. Barrington Research reduced their price objective on Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. StockNews.com lowered shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, November 4th.

Anika Therapeutics Stock Down 1.2 %

Shares of Anika Therapeutics stock opened at $17.04 on Tuesday. Anika Therapeutics, Inc. has a fifty-two week low of $16.00 and a fifty-two week high of $29.11. The business’s fifty day moving average is $22.96 and its two-hundred day moving average is $25.02. The firm has a market cap of $249.64 million, a PE ratio of -2.56 and a beta of 0.86.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.